<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991428</url>
  </required_header>
  <id_info>
    <org_study_id>18/NW/0762</org_study_id>
    <nct_id>NCT04991428</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1</brief_title>
  <official_title>Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intellectual impairment, particularly working memory deficits are a significant cause of&#xD;
      morbidity in children with Neurofibromatosis type (NF1) with long-term implications on&#xD;
      academic and occupational functioning. Whilst significant discoveries have been made in Nf1&#xD;
      animal models in trying to find treatments for these conditions, human translational studies&#xD;
      have not been successful. This mechanistic experimental study will investigate the neural&#xD;
      mechanisms underlying working memory deficits in NF1. In particular, we will investigate how&#xD;
      individual differences in inhibitory neurotransmitter GABA relate to performance on working&#xD;
      memory tests. Further, we will investigate the use of a novel, experimental intervention&#xD;
      called transcranial Direct Current Stimulation (tDCS);known to modulate GABA. Using a&#xD;
      randomized, crossover design in a cohort of 30 adolescents aged 11-17 years, we will apply&#xD;
      real or sham tDCS to the dorsolateral prefrontal cortex (DLPFC). State-of-art real time&#xD;
      imaging techniques such as Magnetic Resonance Spectroscopy (MRS) and task based functional&#xD;
      MRI (fMRI) will be used to investigate the effect of tDCS on GABA concentration, changes in&#xD;
      functional plasticity and working memory. We expect that results from this study will help&#xD;
      elucidate the neural mechanisms underlying working memory deficits in people with NF1 and&#xD;
      show biologic activity for a novel, low-cost intervention that can be used for cognitive&#xD;
      remediation in NF1. This kind of focused mechanism trial method is a highly promising&#xD;
      approach to understanding the complex neural system pathology in a multifactorial&#xD;
      neurodevelopmental condition like NF1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">February 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blind cross over experimental trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corsi Block task</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>memory span task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Neurofibromatosis 1</condition>
  <arm_group>
    <arm_group_label>Active trancranial direct current stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active stimulation for 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Similar set-up but no actual stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcranial direct current stimulation</intervention_name>
    <description>tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.</description>
    <arm_group_label>Active trancranial direct current stimulation</arm_group_label>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets National Institute of Health NF1 diagnostic criteria&#xD;
&#xD;
          2. Children aged 11-17 years&#xD;
&#xD;
          3. Written informed consent/assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No history of intracranial pathology other than asymptomatic optic pathway glioma or&#xD;
             other asymptomatic and untreated NF1-associated white matter lesion&#xD;
&#xD;
          2. No history of epilepsy or any major mental illness&#xD;
&#xD;
          3. No MRI contraindications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Dr Shruti Garg</investigator_full_name>
    <investigator_title>Clinical Senior Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Collected data will be available to share after publication of study findings</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will be made available upon request.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

